Hennessy D R, Steel J W, Prichard R K, Lacey E
CSIRO Division of Animal Health, McMaster Laboratory, Glebe, NSW, Australia.
J Vet Pharmacol Ther. 1992 Mar;15(1):10-8. doi: 10.1111/j.1365-2885.1992.tb00981.x.
The effect of intraruminal administration of parbendazole (PBZ) on the flow rate of bile and the pharmacokinetic behaviour of oxfendazole (OFZ) was examined in sheep. PBZ given at 18, 9 and 4.5 mg/kg resulted in a dose-related reduction in bile flow rate which was also inversely related to changing concentration of PBZ and its metabolites in plasma. Co-administration of 4.5 mg PBZ/kg with 5.0 mg [14C]-OFZ/kg resulted in increased concentrations of fenbendazole (FBZ), OFZ and fenbendazole sulphone (FBZ-SO2) in plasma, although total 14C levels remained unchanged compared with that observed when OFZ alone was administered. The presence of PBZ also reduced biliary secretion of 14C by 22% and altered the relative proportions of OFZ metabolites in bile during the 72-h experimental period. The ratio of 4'-hydroxy-OFZ (OH-OFZ) to 4'-hydroxy-FBZ (OH-FBZ) changed from 7:1 in the absence of PBZ to approximately 1:1 in the presence of PBZ. There was no change in urinary or faecal 14C excretion. The PBZ-induced effects were temporary since the pharmacokinetic behaviour of OFZ given alone two weeks before was similar to that given two weeks after PBZ co-administration. It is suggested that the presence of PBZ temporarily slowed hepatic metabolism and biliary secretion of OFZ metabolites but concomitantly increased extra-biliary transfer of OFZ and/or its metabolites from plasma into the gastrointestinal tract. Elevated exposure of parasites in the gut wall to plasma-derived drug, coupled with higher concentrations of anthelmintically active OH-FBZ secreted in bile, could contribute to the previously reported increased efficacy of OFZ when co-administered with PBZ.
研究了在绵羊瘤胃内给予巴苯达唑(PBZ)对胆汁流速和奥芬达唑(OFZ)药代动力学行为的影响。以18、9和4.5mg/kg的剂量给予PBZ,导致胆汁流速呈剂量相关的降低,这也与血浆中PBZ及其代谢物浓度的变化呈负相关。将4.5mg PBZ/kg与5.0mg [14C]-OFZ/kg共同给药,导致血浆中芬苯达唑(FBZ)、OFZ和芬苯达唑砜(FBZ-SO2)的浓度升高,尽管与单独给予OFZ时相比,总14C水平保持不变。PBZ的存在还使14C的胆汁分泌减少了22%,并在72小时的实验期内改变了胆汁中OFZ代谢物的相对比例。4'-羟基-OFZ(OH-OFZ)与4'-羟基-FBZ(OH-FBZ)的比例从无PBZ时的7:1变为有PBZ时的约1:1。尿液或粪便中14C的排泄没有变化。PBZ诱导的效应是暂时的,因为在PBZ共同给药前两周单独给予的OFZ的药代动力学行为与共同给药后两周给予的相似。有人认为,PBZ的存在暂时减缓了肝脏对OFZ代谢物的代谢和胆汁分泌,但同时增加了OFZ和/或其代谢物从血浆到胃肠道的胆汁外转移。肠道壁中的寄生虫对血浆来源药物的暴露增加,再加上胆汁中分泌的具有驱虫活性的OH-FBZ浓度较高,可能是之前报道的OFZ与PBZ共同给药时疗效增加的原因。